Development and application of hepatocellular carcinoma risk prediction model based on clinical characteristics and liver related indexes

doi:10.4251/wjgo.v15.i8.1486

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2078)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

WORD

HTML

928

Figures (1-3)

134

Tables (1-4)

125

Sum=1281

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

129

Download

554

Sum=683

Aug 15, 2023 (publication date) through May 20, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastrointest Oncol. Aug 15, 2023; 15(8): 1486-1496
Published online Aug 15, 2023. doi: 10.4251/wjgo.v15.i8.1486

Table 1 Characteristics of the study population (n = 2206)

Characteristic	Training cohort		Validation cohort
Characteristic	HCC (n = 496)	Non-HCC (n = 1243)	HCC (n = 156)	Non-HCC (n = 311)
Age (yr)	57.86 ± 11.89^a	53.84 ± 14.53	58.47 ± 11.87^b	54.33 ± 13.53
Gender
Male, n (%)	411 (82.9)^a	759 (61.1)	131 (84.0)^b	169 (54.3%)
Female, n (%)	85 (17.1)^a	484 (38.9)	25 (16.0)^b	142 (45.7%)
PIVKA-II, mAU/mL	1321.03 (117.91-9792.97)^a	24.04 (18.21-37.02)	1337.95 (92.76-11380.07)^b	22.69 (16.92-32.41)
AFP, ng/mL	178.65 (8.33-6474.00)^a	3.60 (1.80-11.75)	145.45 (6.25-2439.10)^b	3.70 (1.90-8.75)
TBIL, μmol/L	21.20 (15.60-31.85)^a	29.80 (15.70-127.50)	21.20 (14.43-32.73)^b	27.40 (15.45-94.05)
GGT, IU/L	130.00 (59.75-279.75)^a	78.20 (29.00-197.00)	145.40 (60.75-272.75)^b	63.00 (25.00-168.35)
AST, U/L	61.10 (38.00-110.00)^a	56.00 (28.00-178.00)	60.00 (37.00-102.83)^b	49.00 (25.00-147.80)
ALT, U/L	42.00 (26.00-70.00)^a	44.00 (21.00-210.85)	43.00 (25.57-68.00)^b	37.00 (19.50-149.00)
TBA, μmol/L	11.10 (4.50-27.45)^a	18.80 (4.10-123.95)	10.20 (4.27-22.10)^b	16.20 (4.00-97.45)
ALB, g/L	37.10 (32.30-41.40)^a	36.10 (30.00-42.20)	37.75 (34.00-41.42)^b	36.80 (30.85-41.90)
HBsAg
Positive, n (%)	388 (78.2)^a	555 (44.7)	123 (78.8)^b	131 (42.1)
Negative, n (%)	108 (21.8)^a	688 (55.3)	33 (21.2)^b	180 (57.9)
Child Pugh Class
Class A, n (%)	317 (63.9)^a	583 (46.9)	103 (66.0)^b	155 (49.8)
Class B, n (%)	151 (30.4)^a	430 (34.6)	45 (28.8)^b	103 (33.1)
Class C, n (%)	28 (5.6)^a	230 (18.5)	8 (5.1)^b	53 (17.0)

^aP < 0.05, compared with non-hepatocellular carcinoma group in training cohort.

^bP < 0.05, compared with non-hepatocellular carcinoma group in validation cohort.

Data are presented as mean standard deviation, median (interquartile range), or numbers (%). HBsAg: Hepatitis B surface antigen; TBA: Total bile acid; TBIL: Total bilirubin; GGT: Gamma-glutamyl transferase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; AFP: Alpha-fetoprotein; PIVKA-II: Protein induced by vitamin K absence or antagonist-II; HCC: Hepatocellular carcinoma; ALB: Albumin.

Table 2 Alpha-fetoprotein, protein induced by vitamin K absence or antagonist-II, or both in the diagnosis of hepatocellular carcinoma

	Training cohort					Validation cohort
	AUC (95%CI)	SEN (%)	SPE (%)	PPV (%)	NPV (%)	AUC (95%CI)	SEN (%)	SPE (%)	PPV (%)	NPV (%)
HCC
AFP	0.812 (0.788-0.815)	49.19	93.00	42.21	94.63	0.845 (0.786-0.880)	52.56	91.00	49.04	92.09
PIVKA-II	0.882 (0.865-0.903)	63.91	94.93	51.21	96.93	0.878 (0.839-0.916)	64.74	94.53	57.35	95.93
AFP + PIVKA-II	0.896 (0.877-0.915)	69.35	95.82	55.51	97.65	0.888 (0.851-0.924)	67.95	95.17	59.83	96.56
Early-stage HCC
AFP	0.860 (0.792-0.928)	51.06	97.49	82.77	89.40	0.714 (0.642-0.787)	14.55	98.49	72.70	80.66
PIVKA-II	0.863 (0.790-0.936)	40.43	96.98	75.97	87.33	0.868 (0.802-0.935)	52.73	96.48	80.55	88.07
AFP + PIVKA-II	0.923 (0.869-0.978)	63.83	96.98	83.31	91.90	0.869 (0.804-0.933)	50.91	95.98	77.78	87.61

SEN: Sensitivity; SPE: Specificity; PPV: Positive predictive value; NPV: Negative predictive value; CI: Confidence interval; PIVKA-II: Protein induced by vitamin K absence or antagonist-II; HCC: Hepatocellular carcinoma; AUC: Area under receiver operating characteristic curve; AFP: Alpha-fetoprotein.

Table 3 Diagnostic performance of hepatocellular carcinoma, early hepatocellular carcinoma, and different subgroups of hepatocellular carcinoma in the NSMC-hepatocellular carcinoma model

	Cut-off value	Training cohort					Validation cohort
	Cut-off value	AUC (95%CI)	SEN (%)	SPE (%)	PPV (%)	NPV (%)	AUC (95%CI)	SEN (%)	SPE (%)	PPV (%)	NPV (%)
HCC	0.22	0.960 (0.950-0.971)	94.40	95.35	87.25	98.10	0.966 (0.945-0.986)	90.00	94.20	89.87	95.47
Early HCC		0.946 (0.901-0.991)	85.93	93.62	61.11	98.28	0.947 (0.901-0.994)	89.10	98.49	94.23	97.02

SEN: Sensitivity; SPE: Specificity; PPV: Positive predictive value; NPV: Negative predictive value; CI: Confidence interval; HCC: Hepatocellular carcinoma; AUC: Area under receiver operating characteristic curve; AFP: Alpha-fetoprotein.

Table 4 Proposed risk scale and corresponding probability of predictive risk of hepatocellular carcinoma

Risk level	Probability of risk	PPV (%)	NPV (%)
Low risk	0.000-0.007	NA	≥ 99.00
Moderate risk	0.008-0.220	NA	< 99.00
High risk	0.221-0.940	< 99.00	NA
Most likely HCC	0.941-1.000	≥ 99.00	NA

NA: Not applicable; PPV: Positive predictive value; NPV: Negative predictive value; HCC: Hepatocellular carcinoma.

Citation: Liu ZJ, Xu Y, Wang WX, Guo B, Zhang GY, Luo GC, Wang Q. Development and application of hepatocellular carcinoma risk prediction model based on clinical characteristics and liver related indexes. World J Gastrointest Oncol 2023; 15(8): 1486-1496
URL: https://www.wjgnet.com/1948-5204/full/v15/i8/1486.htm
DOI: https://dx.doi.org/10.4251/wjgo.v15.i8.1486